Tezepelumab was linked to significantly reduced nasal polyp size and nasal congestion vs placebo in adults with severe CRSwNP.

SinoMab BioScience Limited (Stock Code: 3681.HK, “SinoMab” or the “Company”), is pleased to announce our breakthrough topline results from the completed Phase 1b clinical study evaluating SM17, a ...